Table 1.
Patient characteristics
| Demographics | Patients (n = 10) |
|---|---|
| Age, y | |
| Mean | 68 |
| Range | 56‐75 |
| Sex, no. (%) | |
| Male | 5 (50%) |
| Female | 5 (50%) |
| ECOG performance status, no. (%) | |
| 0 | 6 (60%) |
| 1 | 4 (40%) |
| LDH, no. (%) | |
| ≤ULN | 5 (50%) |
| >ULN | 5 (50%) |
| Primary ocular therapy, no. (%) | |
| Enucleation | 5 (50%) |
| Radiotherapy/brachytherapy | 5 (50%) |
| Prior treatment for advanced disease, no. (%) | |
| Surgery | 1 (10%) |
| Anti‐PD‐1/PD‐L1 | 1 (10%) |
| Anti‐CTLA‐4 | 1 (10%) |
| None | 7 (70%) |
| Post embolization treatment ‐ no. (%) | |
| Anti‐PD‐1 | 7 (70%) |
| Anti‐CTLA‐4 | 1 (10%) |
| None | 2 (20%) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase, ULN, UpperLimit Normal.